LLY vs NVO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 42x trailing and 27x forward earnings, and roughly 14x sales, as of October 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LLY if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and NVO guides.

LLY. At about $1,266 a share on October 16, 2026, Eli Lilly is valued near $1.13 trillion, roughly 42x trailing earnings and 27x the roughly $47.48 in EPS analysts expect for 2027. That premium rests on revenue growth near 48% in the latest quarter and margins (about 54% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the October 29 third-quarter report (consensus about $7.16 EPS on $22.45 billion revenue) is the next data point.

NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9x trailing and 11x forward earnings in October 2026 it now trades at a discount that reflects slowing sales and share loss to Eli Lilly. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; Q3 2026 results are due November 4.

Headline figures (approximate, October 2026): LLY shows revenue (ttm) ~$79.7 billion, q2 2026 revenue ~$23.0 billion (up ~48% YoY), q2 2026 eps $8.38 vs ~$6.58 est., gross / operating margin (ttm) ~83% / ~54%; NVO shows revenue (ttm) ~DKK 329 billion (+2% YoY in Q2 2026), revenue (2026 consensus) ~DKK 301 billion, operating margin (ttm) ~43%, net margin (ttm) ~35%.

LLY and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and NVO exposure against your real portfolio. It is not an investment adviser.